These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
503 related articles for article (PubMed ID: 11772129)
61. Chemotherapy of prostate cancer: present and future. Trump D; Lau YK Curr Urol Rep; 2003 Jun; 4(3):229-32. PubMed ID: 12756087 [TBL] [Abstract][Full Text] [Related]
62. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience. DiBlasio CJ; Malcolm JB; Hammett J; Wan JY; Aleman MA; Patterson AL; Wake RW; Derweesh IH BJU Int; 2009 Nov; 104(9):1208-14. PubMed ID: 19388987 [TBL] [Abstract][Full Text] [Related]
63. Novel chemotherapies in development for management of castration-resistant prostate cancer. Tewari AK; George DJ Curr Opin Urol; 2013 May; 23(3):220-9. PubMed ID: 23511791 [TBL] [Abstract][Full Text] [Related]
64. Actual chemotherapeutical possibilities in hormone-refractory prostate cancer (HRPC) patients. Prezioso D; Galasso R; Di Martino M; Iapicca G; Annunziata E; Iacono F Anticancer Res; 2007; 27(2):1095-104. PubMed ID: 17465249 [TBL] [Abstract][Full Text] [Related]
65. Oral combination of cyclophosphamide, uracil plus tegafur and estramustine for hormone-refractory prostate cancer. Nishimura K; Nonomura N; Ono Y; Nozawa M; Fukui T; Harada Y; Imazu T; Takaha N; Sugao H; Miki T; Okuyama A Oncology; 2001; 60(1):49-54. PubMed ID: 11150908 [TBL] [Abstract][Full Text] [Related]
66. First-line use of novel hormonal agents in prostate cancer: a critical appraisal. Raghavan D Clin Adv Hematol Oncol; 2018 Apr; 16(4):289-295. PubMed ID: 29742084 [TBL] [Abstract][Full Text] [Related]
71. [Therapy of hormone refractory prostate cancer: new standards, new trends]. Wülfing C; Bierer S; Bögemann M; Piechota H; Hertle L Aktuelle Urol; 2005 Aug; 36(4):342-8. PubMed ID: 16110408 [TBL] [Abstract][Full Text] [Related]
72. Novel approaches to treating the asymptomatic hormone-refractory prostate cancer patient. Gulley J; Dahut WL Urology; 2003 Dec; 62 Suppl 1():147-54. PubMed ID: 14747053 [TBL] [Abstract][Full Text] [Related]
73. A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients. Koutsilieris M; Mitsiades C; Dimopoulos T; Ioannidis A; Ntounis A; Lambou T J Clin Endocrinol Metab; 2001 Dec; 86(12):5729-36. PubMed ID: 11739429 [TBL] [Abstract][Full Text] [Related]
74. Management of hormone refractory prostate cancer: current standards and future prospects. Oh WK; Kantoff PW J Urol; 1998 Oct; 160(4):1220-9. PubMed ID: 9751323 [TBL] [Abstract][Full Text] [Related]
75. Metastatic castrate-resistant prostate cancer: dawn of a new age of management. Masson S; Bahl A BJU Int; 2012 Oct; 110(8):1110-4. PubMed ID: 22564337 [TBL] [Abstract][Full Text] [Related]
76. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter? Michels J; Montemurro T; Murray N; Kollmannsberger C; Nguyen Chi K Cancer; 2006 Mar; 106(5):1041-6. PubMed ID: 16456811 [TBL] [Abstract][Full Text] [Related]